Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.34 |
| ▸ | CNR2 | P34972 | 12/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15069897 | 0.87 | CNR1 (0.32) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL26033956 | 0.82 | CYP3A4 (0.36) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL13192102 | 0.78 | CNR1 (0.35) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL9607545 | 0.78 | GAA (0.42) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL15069883 | 0.78 | GRN (0.38) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL24007032 | 0.76 | CNR1 (0.34) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL21720383 | 0.76 | CNR1 (0.34) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL21721730 | 0.76 | CNR1 (0.35) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL21721455 | 0.76 | CNR1 (0.34) | CNR1CNR2ADORA2AADORA2B | |
| SCHEMBL23403195 | 0.76 | CNR1 (0.37) | CNR1CNR2ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | IAPP, APP, BACE1 | CNR1 1755/4885CNR2 2543/4885ADORA2A 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.